1. Demetri GD, von Mehren M, Jones RL, et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol Mar 10;34(8) (2016) 786–793. doi: 10.1200/JCO. 2015.62.4734. Epub 2015 Sep 14.
2. Demetri GD, Schöffski P, Grignani G, et al. Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.J Clin Oncol Oct 20;35(30) (2017) 3433–3439. doi: 10.1200/JCO. 2016.71.6605. Epub 2017 Aug 30.
3. Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol Jun;18(6) (2017) 812–822. doi: 10.1016/S1470-2045(17)30334-0. Epub 2017 May 9. Erratum in: Lancet Oncol. 2017 Jun;18(6):e301.
4. Issels RD, Lindner LH, Verweij J, et al. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial. JAMA Oncol Apr 1;4(4) (2018) 483–492. doi: 10.1001/jamaoncol.2017.4996.
5. Joensuu H, Eriksson M, Sundby Hall K, et al. Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. J Clin Oncol Jan 20;34(3) (2016) 244-250. doi: 10.1200/JCO. 2015.62.9170. Epub 2015 Nov 2.